| scholarly article | Q13442814 |
| P2093 | author name string | Candace S Johnson | |
| Donald L Trump | |||
| Marwan G Fakih | |||
| Josephia R Muindi | |||
| Kristie L Engler | |||
| Renee Christy | |||
| P2860 | cites work | New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 |
| A Phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy | Q28368222 | ||
| Activation of extracellular signal-regulated kinases (ERKs) defines the first phase of 1,25-dihydroxyvitamin D3-induced differentiation of HL60 cells | Q31910647 | ||
| Conventional treatment of hypercalcemia of malignancy. | Q34470651 | ||
| 1alpha,25-Dihydroxyvitamin D3 potentiates cisplatin antitumor activity by p73 induction in a squamous cell carcinoma model | Q36982956 | ||
| Intestinal calcium absorption in exogenous hypercortisonism. Role of 25-hydroxyvitamin D and corticosteroid dose | Q37045709 | ||
| Differential antiproliferative effects of calcitriol on tumor-derived and matrigel-derived endothelial cells | Q38310048 | ||
| Growth regulation of human colon cancer cells by epidermal growth factor and 1,25-dihydroxyvitamin D3 is mediated by mutual modulation of receptor expression | Q40968454 | ||
| Transforming growth factor-beta potentiates vitamin D3-induced terminal monocytic differentiation of human leukemic cell lines | Q41565934 | ||
| Differentiating and antitumor activities of 1 alpha,25-dihydroxyvitamin D3 in vitro and 1 alpha-hydroxyvitamin D3 in vivo on human osteosarcoma | Q41581472 | ||
| Prolonged hypercalcaemia after industrial exposure to vitamin D3. | Q41841677 | ||
| Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. | Q43579777 | ||
| A Phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation | Q43645557 | ||
| Combination of 1alpha,25-dihydroxyvitamin D(3) with dexamethasone enhances cell cycle arrest and apoptosis: role of nuclear receptor cross-talk and Erk/Akt signaling. | Q43829476 | ||
| Cisplatin potentiates 1,25-dihydroxyvitamin D3-induced apoptosis in association with increased mitogen-activated protein kinase kinase kinase 1 (MEKK-1) expression. | Q44255811 | ||
| Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel | Q44259177 | ||
| Pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 in normal mice after systemic exposure to effective and safe antitumor doses | Q44805762 | ||
| Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer | Q46797226 | ||
| Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy | Q51647891 | ||
| A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors. | Q53577477 | ||
| Suppression of in vivo growth of human cancer solid tumor xenografts by 1,25-dihydroxyvitamin D3 | Q70156729 | ||
| Antiproliferative responses to two human colon cancer cell lines to vitamin D3 are differently modified by 9-cis-retinoic acid | Q70908424 | ||
| Vitamin D3 analogue (EB 1089) inhibits in vitro cellular proliferation of human colon cancer cells | Q71213104 | ||
| Enhancement of 1,25-dihydroxyvitamin D3-mediated antitumor activity with dexamethasone | Q74121283 | ||
| 1,25-Dihydroxycholecalciferol (1,25-D3) inhibits the growth of squamous cell carcinoma and down-modulates p21(Waf1/Cip1) in vitro and in vivo | Q77861542 | ||
| Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer | Q79303399 | ||
| P433 | issue | 1 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| dexamethasone | Q422252 | ||
| P304 | page(s) | 33-40 | |
| P577 | publication date | 2009-04-26 | |
| P1433 | published in | Cancer Chemotherapy and Pharmacology | Q326137 |
| P1476 | title | A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors | |
| P478 | volume | 65 |
| Q34778161 | 1α,25-Dihydroxyvitamin D3-3β-bromoacetate, a potential cancer therapeutic agent: synthesis and molecular mechanism of action |
| Q84596826 | A phase I study of the vitamin D3 analogue ILX23-7553 administered orally to patients with advanced solid tumors |
| Q36799473 | A phase I/II pharmacokinetic and pharmacogenomic study of calcitriol in combination with cisplatin and docetaxel in advanced non-small-cell lung cancer |
| Q34689137 | A vitamin D receptor-alkylating derivative of 1α,25-dihydroxyvitamin D3 inhibits growth of human kidney cancer cells and suppresses tumor growth. |
| Q39670398 | Calcitriol (1,25-dihydroxycholecalciferol) enhances mast cell tumour chemotherapy and receptor tyrosine kinase inhibitor activity in vitro and has single-agent activity against spontaneously occurring canine mast cell tumours* |
| Q61023219 | Calcitriol and cancer therapy: A missed opportunity |
| Q26766242 | Calcitriol in Combination Therapy for Prostate Cancer: Pharmacokinetic and Pharmacodynamic Interactions |
| Q38020247 | Current progress in using vitamin D and its analogs for cancer prevention and treatment |
| Q41461266 | GSK-3 Inhibition Sensitizes Acute Myeloid Leukemia Cells to 1,25D-Mediated Differentiation |
| Q39282066 | Nitric oxide release from trigeminal satellite glial cells is attenuated by glial modulators and glutamate |
| Q50309039 | Oral bioavailability of DN101, a concentrated formulation of calcitriol, in tumor-bearing dogs |
| Q43158086 | Phase 2 trial of weekly intravenous 1,25 dihydroxy cholecalciferol (calcitriol) in combination with dexamethasone for castration-resistant prostate cancer |
| Q37761548 | The role of vitamin D in cancer prevention and treatment |
| Q38004753 | The role of vitamin D in cancer prevention and treatment |
| Q36509508 | Vitamin D and cancer: clinical aspects |
| Q26739735 | Vitamin D and urological cancers |
| Q55024961 | Vitamin D in prostate cancer. |
| Q37803065 | Vitamin D supplementation: a pharmacologic perspective |
| Q37814083 | Vitamin D, disease and therapeutic opportunities |
| Q37061744 | Vitamin d: pharmacokinetics and safety when used in conjunction with the pharmaceutical drugs used in cancer patients: a systematic review |
Search more.